Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Sep 14, 2026
Revenue (TTM)
$329.43B
+2.1% YoY
Gross margin
82.0%
EPS (latest q)
$0.96
vs $0.82 est · beat
52-wk position
32.5%
-29.5% vs 52w high · -6.6% 1mo
Price (last ~year)
Novo Nordisk (NVO) shares have declined 9.3% over the past five days following a downgrade by Morgan Stanley citing potential market share losses and the termination of two Phase 3 heart disease studies. While the company recently secured Chinese regulatory approval for Wegovy and reported positive pediatric trial results, it faces a 20.6% year-over-year decline in earnings. The stock currently trades at $43.07, reflecting a P/E ratio of 10.53 and a market capitalization of $190.32 billion against trailing twelve-month revenue of $329.43 billion.
Valuation
- Market cap
- $190.32B
- P/E
- 10.53
- PEG
- 3.04
- P/B
- 5.53
- P/S
- 0.578
- EV/EBITDA
- 8.91
- Beta
- 0.344
- Analyst target
- $47.23
Quality & returns
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Profit margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
Price movement
- Last
- $43.07
- 1-month
- -6.6%
- 3-month
- +0.2%
- RSI (14)
- 35
- vs SMA200
- -4.4%
- 52-wk position
- 32.5% -29.5% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $78.49B | $27.06B | $20.99B | $38.68B |
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
Recent news
- Somewhat-Bearish Novo Nordisk Stock (NVO) Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff · 2026-09-12
- Neutral Novo Nordisk says Wegovy approved in China for liver disease MASH · 2026-09-10
- Bearish Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’ · 2026-09-08
- Bullish Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial · 2026-09-08
- Neutral Why the CEO of Wegovy maker Novo Nordisk isn't yet sold on the peptide craze · 2026-09-08
- Neutral Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial · 2026-09-07
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)